Medtronic Competitors

Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Medtronic and Abbott Laboratories' top-line revenue, earnings per share and valuation.

Medtronic has higher earnings, but lower revenue than Abbott Laboratories. Medtronic is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Medtronic and Abbott Laboratories' net margins, return on equity and return on assets.

Risk and Volatility

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Medtronic and Abbott Laboratories, as reported by MarketBeat.com.

Medtronic presently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Abbott Laboratories has a consensus price target of $115.3750, suggesting a potential upside of 8.42%. Given Abbott Laboratories' higher probable upside, analysts clearly believe Abbott Laboratories is more favorable than Medtronic.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.0%. Abbott Laboratories pays an annual dividend of $1.44 per share and has a dividend yield of 1.4%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Abbott Laboratories pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 43 consecutive years and Abbott Laboratories has raised its dividend for 48 consecutive years.

Summary

Abbott Laboratories beats Medtronic on 10 of the 18 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares Medtronic and Stryker's top-line revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Stryker. Medtronic is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Medtronic and Stryker's net margins, return on equity and return on assets.

Risk and Volatility

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Medtronic and Stryker, as reported by MarketBeat.com.

Medtronic presently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Stryker has a consensus price target of $221.44, suggesting a potential downside of 5.25%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than Stryker.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.0%. Stryker pays an annual dividend of $2.30 per share and has a dividend yield of 1.0%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Stryker pays out 27.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has raised its dividend for 43 consecutive years and Stryker has raised its dividend for 1 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Medtronic beats Stryker on 9 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Risk and Volatility

Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500.

Earnings and Valuation

This table compares Medtronic and Intuitive Surgical's gross revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Intuitive Surgical. Medtronic is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Intuitive Surgical's net margins, return on equity and return on assets.

Insider & Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are held by institutional investors. 0.5% of Medtronic shares are held by insiders. Comparatively, 1.6% of Intuitive Surgical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Medtronic and Intuitive Surgical, as reported by MarketBeat.com.

Medtronic presently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Intuitive Surgical has a consensus price target of $718.2778, suggesting a potential downside of 1.11%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats Medtronic on 9 of the 15 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Volatility and Risk

Medtronic has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Medtronic and Becton, Dickinson and's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Becton, Dickinson and. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Dividends

Medtronic pays an annual dividend of $2.32 per share and has a dividend yield of 2.0%. Becton, Dickinson and pays an annual dividend of $3.16 per share and has a dividend yield of 1.4%. Medtronic pays out 50.5% of its earnings in the form of a dividend. Becton, Dickinson and pays out 31.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Medtronic has increased its dividend for 43 consecutive years and Becton, Dickinson and has increased its dividend for 49 consecutive years.

Profitability

This table compares Medtronic and Becton, Dickinson and's net margins, return on equity and return on assets.

Insider and Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Medtronic and Becton, Dickinson and, as reported by MarketBeat.com.

Medtronic currently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Becton, Dickinson and has a consensus price target of $280.2857, suggesting a potential upside of 23.22%. Given Becton, Dickinson and's higher probable upside, analysts clearly believe Becton, Dickinson and is more favorable than Medtronic.

Summary

Medtronic beats Becton, Dickinson and on 10 of the 17 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares Medtronic and Edwards Lifesciences' gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Edwards Lifesciences' net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are held by institutional investors. 0.5% of Medtronic shares are held by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Medtronic and Edwards Lifesciences, as reported by MarketBeat.com.

Medtronic currently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Edwards Lifesciences has a consensus price target of $87.7222, suggesting a potential upside of 4.17%. Given Medtronic's stronger consensus rating and higher probable upside, equities research analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Summary

Medtronic beats Edwards Lifesciences on 8 of the 15 factors compared between the two stocks.

Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

Medtronic has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Valuation and Earnings

This table compares Medtronic and Boston Scientific's gross revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and Boston Scientific's net margins, return on equity and return on assets.

Institutional & Insider Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 82.7% of Boston Scientific shares are held by institutional investors. 0.5% of Medtronic shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Medtronic and Boston Scientific, as reported by MarketBeat.com.

Medtronic currently has a consensus price target of $122.00, suggesting a potential upside of 7.67%. Boston Scientific has a consensus price target of $43.80, suggesting a potential upside of 30.55%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Medtronic.

Summary

Boston Scientific beats Medtronic on 8 of the 15 factors compared between the two stocks.